Floatz logo

Glibenclamide

Blood Pressure

University of Campinas, BrazilSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Blood Pressure cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
Yuhan Corporation
Phase 4BBB
AMLODIPINE
Yuhan Corporation
Phase 4BBB
Phentermine
VIVUS LLC
Phase 4BB
VALSARTAN
ARKAY Therapeutics
Phase 4BB
LABETALOL
ProMedica Health System
Phase 3BB

View all 44 →

Same molecule, other indications

Glibenclamide is also rated in:

diabetes mellitusDormant
BBB
Indicative ·
76 / 100
View asset →
hypertrophic cardiomyopathyDormant
BB
Indicative ·
69 / 100
View asset →
arteriosclerosis disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →